20th Annual Scientific Meeting
21 – 23 February, 2024 // Washington, DC
Distinguished Poster Award Recipients:
|
|||
|
Measuring remission and response using CDRS-R and MADRS: An analysis in adolescents with MDD and imminent risk for suicide (abstract) – Cai Shi Relationship between sample size and responsiveness of speech-based digital biomarkers in ALS (Abstract) – Kothare Estimating heterogeneity of treatment effects in clinical trials (Abstract) – Siegel |
|||
|
All Poster PDFs and Abstracts are available here. |
|||
21 February 2024 |
|||
| Welcome from the President | Gary Sachs slides video |
||
| Andrew C. Leon Distinguished Career Award Presentation | Gary Sachs Luca Pani slidesRichard Keefe video |
||
| ISCTM 20th Anniversary Session – Advancements & what can we do better in the future | Chairs: Amir Kalali Michael Ropacki |
||
| Introduction and overview
|
Amir Kalali slides video |
||
| Overview of methodological advancements & room for improvement | Michael Ropacki slides video |
||
| Real world evidence data from drug registration to reimbursement | Luca Pani slides video |
||
| Diversity, equity, and inclusion in clinical trials | Carla Canuso slides video |
||
| Adoption of novel clinical endpoints | Kemi Olugemo slides video |
||
| Digital biomarkers and health measurement in clinical trials | Anzar Abbas slides video |
||
| Impact of external factors on the future of CNS therapy development | George Garibaldi slides video |
||
| Panel Discussion | Facilitators: Amir Kalali Michael Ropacki video |
||
|
Wednesday Working Group Sessions |
|||
| Developing Strategies to Improve Recruitment for Clinical Trials Targeting Neuropsychiatric Symptoms (NPS) in Memory Disorders Working Group | Chairs: Moyra Mortby Paul Rosenberg slidessummary |
||
| Diversity in CNS Clinical Trials Working Group | Chairs: Abhishek Pratap Siân Ratcliffe slides |
||
| Methodological Issues in Study Designs for Clinical Trials with Psychedelics Working Group | Chairs: Amir Inamdar Joyce Tsai summary |
||
| Negative Symptoms Working Group | Chairs: David Daniel Stephen Marder summary |
||
| Orphan Diseases Working Group | Chairs: Joan Busner Gahan Pandina summary slides |
||
| 20th Annual Celebration and Founders Reception | Gary Sachs George Awad slideshow video |
||
22 February 2024 |
|||
| Lewis Alan Opler Prize Presentation | Gary Sachs Mark Opler slidesSeth Hopkins slides video |
||
| Use of existing data to inform and speed development of personalized medicine for CNS disorders | Chairs: Larry Alphs Ole Andreassen |
||
| Introduction: The vision for precision medicine and goals of the session | Larry Alphs slides video |
||
| CNS precision medicine: From research to real-world impact | Ole Andreassen slides video |
||
| Discovery and validation of a genetic biomarker for a triple reuptake inhibitor (liafensine) in TRD | Wen Luo slides video |
||
| Biomarker identification for patient enrichment strategies in CNS clinical trials: Alternative approaches and challenges | Joseph Geraci slides video |
||
| Using digital technologies to develop holistic patient-centered solutions for improving mental health outcomes | Abhishek Pratap* video |
||
| Nordic networks for precision medicine research | Hakon Heimer slides video |
||
| User perspectives on precision psychiatry | Tineke Mollema slides video |
||
| Statistical principles and considerations for precision medicine in psychiatry and neurology: A regulatory perspective | Sue-Jane Wang slides video |
||
| Panel Discussion | Facilitator: Larry Alphs video |
||
| How to Implement the Estimand Framework in Clinical Trials – Examples, Examples, Examples | Chairs: Elena Polverejan Marc Walton |
||
| Introduction | Marc Walton slides video |
||
| The interdisciplinary process for implementing the estimand framework, with examples from Major Depressive Disorder | Nanco Hefting Elena Polverejan slides video |
||
| What is the question? The importance of estimand thinking in clinical trials: Alzheimer’s disease example | Jennifer Murphy Stephen Ruberg slides video |
||
| Estimands in CNS trials: A review of strategies accepted by EMA to handle intercurrent events | Lorenzo Guizzaro slides video |
||
| Panel Discussion
|
Discussants: Michael O’Kelly slidesH.M. James Hung (comment provided on his behalf) Marc Walton Facilitators: Elena Polverejan Marc Walton slides video |
||
| Under What Circumstances Could Pediatric Extrapolation Occur? | Chairs: Manpreet Singh Robert Nelson |
||
| Introduction | Manpreet Singh Robert Nelson slides video |
||
| Pediatric extrapolation guidance framework | Lynne Yao slides video |
||
| Optimizing pediatric drug development in psychiatry: Quantitative methods to support extrapolation of efficacy | Shamir Kalaria slides video |
||
| Innovative pediatric trials: A statistical examination of design and analysis strategies | Forrest Williamson slides video |
||
| Pathways for extrapolation in psychiatry | Tiffany Farchione slides video |
||
| A recent example of pediatric extrapolation in psychiatry | Dana Cahill slides video |
||
| Panel Discussion | Facilitator: Robert Nelson video |
||
| Poster Session/Reception | Poster PDFs and Abstracts | ||
23 February 2023
|
|||
|
Friday Working Group Sessions |
|||
| Accelerating Development of Psychopathology Measures – ISCTM/ECNP Join Working Group | Chairs: Nina Schooler Jenicka Engler Celso Arango summary slides |
||
| Advancing the Methods to Evaluate Abuse and Dependence Potential in Clinical Studies for CNS-Active Drugs and Novel Psychedelics Working Group | Chairs: Beatrice Setnik Jadwiga Martynowicz summary slides |
||
| Assessment of Methods and Endpoints for Rapid-Acting Antidepressants-RAADs Working Group | Chairs: Christian Yavorsky Jan Sedway summary slides |
||
| Behavioral and Psychiatric Symptoms in Dementia (BPSD) Apathy Working Group | Chairs: Krista Lanctôt David Miller summary slides |
||
| Digital Biomarkers Decision Process Working Group | Chairs: Vikas Mohan Sharma Anzar Abbas summary slides |
||
| Sleep Methodology in CNS Trials Working Group | Chairs: Margaret Moline Georg Dorffner summary slides |
||
| Digital Health Measurement in CNS: Recruitment, Screening, and Endpoints | Chairs: Anzar Abbas Uma Vaidyanathan |
||
| Introduction | Anzar Abbas slides video |
||
| Objective measurement from subjective clinical interviews: Application to drug development | Seth Hopkins slides video |
||
| The need for broad-spectrum multimodal markers in CNS drug development | Brian Murphy slides video |
||
| The application of large language models to psychiatric measurement | Isaac Galatzer-Levy slides video |
||
| Precision drug development using resting state EEG | Adam Savitz slides video |
||
| Regulatory considerations pertaining to use of digital health measures | Anita Bajaj slides video |
||
| Panel Discussion | Facilitators: Anzar Abbas Uma Vaidyanathan video |
||
| Digital phenotyping in clinical trials: The path ahead | Uma Vaidyanathan slides video |
||
| Meeting Adjourned | Luca Pani video |
||
| *Slides not released | |||